Cediranib is an anti-angiogenesis drug, similar to bevacizumab (Avastin). It works by blocking a type of protein called vascular endothelial growth factors (VEGF).
The body uses VEGF to grow new blood vessels and heal itself. This process is called angiogenesis. However, tumors also rely on angiogenesis to grow and spread cancer cells throughout the body.
Halting angiogenesis can starve tumors and prevent metastasis, but it can also cause severe side effects for patients. The main challenge for researchers is safely adding anti-angiogenesis drugs into chemotherapy regimens.
Cediranib has not been approved by the U.S. Food and Drug Administration. Various clinical trials are testing cediranib for solid tumors, including pleural mesothelioma.
Cediranib in Mesothelioma Clinical Trials
Early clinical trials tested high-dose cediranib after chemotherapy. These high doses resulted in many complications and little benefit. More recent trials have tried lower-dose cediranib in combination with standard chemotherapy. They have also produced weak results.
In 2011, the Journal of Thoracic Oncology published the results of a phase II study. Researchers evaluated 47 pleural mesothelioma patients. The patients received a daily 45 mg dose of cediranib after finishing chemotherapy.
Tumors shrank in four of the patients, but more than half the study group experienced fatigue, diarrhea and high blood pressure. Almost all the patients required a dose reduction.
A 2012 article in Lung Cancer reported the results of a similar phase II trial which evaluated 50 patients. Patients were initially given 45 mg of cediranib each day. The researchers later lowered the dose to 30 mg.
The researchers observed that disease control was better at the higher dose, but it resulted in many severe side effects.
In 2017, the Journal of Thoracic Oncology reported on a phase I trial combining cediranib with standard chemotherapy for pleural mesothelioma. The researchers determined that a 20 mg daily dose of cediranib was reasonably safe to take in between cycles of Alimta (pemetrexed) and cisplatin.
The following year, researchers conducted a phase II trial with 92 pleural mesothelioma patients. Some of the patients received standard chemotherapy and cediranib, while the others received chemotherapy plus a placebo.
Median survival was 10 months for the cediranib group and 8.5 months for the placebo group. The cediranib group was about three times more likely to experience diarrhea and high blood pressure.
Patients interested in experimental treatments should talk to an experienced mesothelioma specialist about which clinical trials may be right for them.
Share this article
Last Modified November 29, 2018
5 Cited Article Sources
Tsao, A. et al. (2018, May 20). SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
Retrieved from: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8514
Tsao, A. et al. (2017, Aug). Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28599887
Campbell, N. et al. (2012, October). Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319647/
Garland, L. et al. (2011. November). Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/21964533
- National Cancer Institute. (n.d.). Cediranib maleate. Retrieved from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cediranib-maleate